Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine·2026
Same author

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Nature biomedical engineering·2026
Same author

Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles.

Transplantation and cellular therapy·2026
Same author

Overcoming functional and translational challenges of cellular immunotherapies for solid tumors.

Cancer cell·2026
Same author

Efficient Production of Chimeric Antigen Receptor (CAR) T Cells with Transgenes Exceeding 10 kb Using Lentiviral Vectors.

Journal of visualized experiments : JoVE·2026
Same author

Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

CXCL13-CXCR5 signaling in CD8<sup>+</sup> T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

Cancer immunology, immunotherapy : CII·2026
Same journal

Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.

Cancer immunology, immunotherapy : CII·2026
Same journal

Correction: Repurposing public sarcoma multi-omics for neoantigen discovery.

Cancer immunology, immunotherapy : CII·2026
Same journal

A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.

Cancer immunology, immunotherapy : CII·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K

Engineered T cells for cancer therapy.

Carl H June1, Marcela V Maus, Gabriela Plesa

  • 1Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 8th Floor, Philadelphia, PA, 19104-5156, USA, cjune@exchange.upenn.edu.

Cancer Immunology, Immunotherapy : CII
|June 20, 2014
PubMed
Summary
This summary is machine-generated.

Synthetic biology offers a promising approach to enhance adoptive T cell transfer for cancer immunotherapy, potentially overcoming limitations in immunocompromised patients.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K

Related Experiment Videos

Last Updated: Apr 28, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K

Area of Science:

  • Immunology
  • Synthetic Biology
  • Cancer Research

Background:

  • The immune system possesses inherent capabilities for cancer cell detection and elimination.
  • Adoptive T cell transfer presents an alternative to vaccines for cancer treatment, especially in immunocompromised individuals.
  • Existing vaccine strategies face significant limitations in effectively treating cancer in compromised immune systems.

Purpose of the Study:

  • To review the application of synthetic biology in cancer immunotherapy.
  • To explore how synthetic biology can enhance adoptive T cell transfer strategies.
  • To highlight the potential of engineered biological systems for improved cancer treatment.

Main Methods:

  • Review of current research in synthetic biology and cancer immunotherapy.
  • Analysis of genetic engineering and molecular biology techniques for creating enhanced T cells.
  • Examination of the integration of synthetic biology principles with adoptive T cell transfer.

Main Results:

  • Synthetic biology enables the engineering of T cells with novel functionalities for cancer targeting.
  • This approach can potentially overcome immune evasion mechanisms employed by cancer cells.
  • Enhanced T cell functionalities can lead to more effective tumor elimination.

Conclusions:

  • Synthetic biology holds significant potential to advance adoptive T cell transfer for cancer treatment.
  • Engineered T cells offer a powerful tool to combat cancer, particularly in challenging patient populations.
  • Further research in synthetic biology is crucial for developing next-generation cancer immunotherapies.